Probiotec Limited engages in the development, manufacture, packing, distribution, and sale of prescription and over the counter pharmaceuticals, complementary medicines and consumer health products, and fast-moving consumer products in Australia and internationally. The company provides contract manufacturing services for solid dose tablets, capsules, and caplets; tablets coatings; blister packs, bottles, sachets, tubs, and tubes; liquids, creams, gels, lotions, ointments, and powders and powder blends. It is also involved in analytical and stability testing services; new product formulation and production trials, and ongoing research and development services; and packaging options for human and animal nutrition products, as well as manufactures and exports a range of nutraceuticals and functional ingredient raw materials. The company was incorporated in 1996 and is headquartered in Laverton North, Australia.
Stock data | 2023 | Change |
---|---|---|
Price | $1.94 | N/A |
Market Cap | $157.92M | N/A |
Shares Outstanding | 81.32M | 1.48% |
Employees | 0 | N/A |
Shareholder Equity | 87.14M | 10.23% |
Valuation | 2023 | Change |
---|---|---|
P/S Ratio | 1.13 | N/A |
P/B Ratio | 1.81 | N/A |
Growth | 2023 | Change |
---|---|---|
Return on Equity | 0.0824 | N/A |
Earnings | 2023 | Change |
---|---|---|
Revenue | $139.47M | N/A |
Earnings | $7.18M | N/A |
Gross Margin | 0.3006 | N/A |
Operating Margin | 0.0313 | N/A |
Net income margin | 0.0515 | N/A |
Financial Strength | 2023 | Change |
---|---|---|
Total Assets | $153.42M | N/A |
Total Debt | $57.28M | N/A |
Cash on Hand | $9.16M | N/A |
Debt to Equity | $1.11 | -15.31% |
Cash to Debt | 0.1599 | -33.05% |
Current Ratio | 0.8076 | -44.35% |